Reduced expression of activating receptors (including NKp30, NKp46, NKp80, CD16, DNAX accessory molecule-1 (DNAM-1) and NKG2D) has been documented in lung carcinoma [108], breast cancer [105] and acute myeloid leukaemia [126]. The gene discussed is CD226; the disease is lung carcinoma.